BH Therapeutics

Biohaven is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative therapies for patients with debilitating neurological and neuropsychiatric diseases, as well as rare disorders. The company gained significant prominence for its CGRP receptor antagonist platform, leading to the FDA approval of Nurtec ODT for migraine. Following the acquisition of its CGRP business by Pfizer in 2022, the company spun off into a new entity, Biohaven Ltd., which retains a diverse pipeline of late-stage assets targeting glutamate modulation, myostatin inhibition, and ion channel activation. Biohaven's current portfolio includes promising candidates for spinal muscular atrophy, obsessive-compulsive disorder, and various neurodegenerative conditions.